Phase I Clinical Trial of the Wee1 inhibitor Adavosertib (AZD1775) with Irinotecan in Children with Relapsed Solid Tumors. A COG Phase 1 Consortium Report (ADVL1312)

PURPOSE: Adavosertib (AZD1775), an inhibitor of WEE1 kinase, potentiates replicative stress induced by oncogenes or chemotherapy. Anti-tumor activity of adavosertib has been demonstrated in preclinical models of pediatric cancer. This phase I trial was performed to define dose-limiting toxicities (D...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Clin Cancer Res
Auteurs principaux: Cole, Kristina A., Pal, Sharmistha, Kudgus, Rachel A., Ijaz, Heba, Liu, Xiaowei, Minard, Charles G., Pawel, Bruce, Maris, John M., Haas-Kogan, Daphne, Voss, Stephan, Berg, Stacey L., Reid, Joel M., Fox, Elizabeth, Weigel, Brenda J.
Format: Artigo
Langue:Inglês
Publié: 2019
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7073289/
https://ncbi.nlm.nih.gov/pubmed/31857431
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-19-3470
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires